Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles G Drake

Showing results (201-210 of 266) with videos related to

Pageof 27
Sort By:
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate CancerCatherine H Marshall, Wei Fu, Hao Wang, et al.
Cancer Cell|April 28, 2023
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulatorsAleksandar Obradovic, Casey Ager, Mikko Turunen, et al.
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.
Journal of the National Cancer Institute|May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational ResearchToni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.
Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.
The Prostate|March 21, 2017
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.
Pageof 27

Showing results (201-210 of 266) with videos related to

Sort By:
Pageof 27
Journal for Immunotherapy of Cancer|December 30, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinomaDouglas G McNeel, Neil H Bander, Tomasz M Beer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate CancerCatherine H Marshall, Wei Fu, Hao Wang, et al.
Cancer Cell|April 28, 2023
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulatorsAleksandar Obradovic, Casey Ager, Mikko Turunen, et al.
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.
Journal of the National Cancer Institute|May 3, 2020
Summary From the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational ResearchToni K Choueiri, Michael B Atkins, Ziad Bakouny, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJulie R Brahmer, Charles G Drake, Ira Wollner, et al.
Prostate Cancer and Prostatic Diseases|July 14, 2021
Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted Listeria monocytogenes-based immunotherapy, in metastatic castration-resistant prostate cancerCharles G Drake, Russell K Pachynski, Sumit K Subudhi, et al.
The Prostate|March 21, 2017
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention TrialDanyelle A Winchester, Cathee Till, Phyllis J Goodman, et al.
Pageof 27